JNJ Q2 sales $23.7B (+5.8%); GAAP EPS $2.29 (+18.7%); adj. EPS $2.77 (-1.8%)

JOHNSON & JOHNSON

2025-Q2 EPS reported $6.82 revenue$45,636,000,000

Q2 sales $23,743M (+5.8% YoY); U.S. $13,544M (+7.8%), International $10,199M (+3.2%).
GAAP net earnings $5,537M; diluted EPS $2.29 vs $1.93 a year ago (+18.7%).
Adjusted net earnings $6,699M; adjusted diluted EPS $2.77 vs $2.82 (-1.8%).
Innovative Medicine sales $15,202M (+4.9%); MedTech sales $8,541M (+7.3%).
Gross margin 67.9% vs 69.4% year ago; R&D expense $3,516M (14.8% of sales).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.